Autifony Therapeutics Limited

In an illustration of Jazz Pharmaceuticals plc ’s focus on central nervous system disorders, the company recently presented 13 posters and oral presentations at the American Academy of Neurology annu

In Vivo's editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2023. Vote now in the polls below. T

Who: Jazz Pharmaceuticals/Autifony Therapeutics What: Jazz and Autifony signed a global licensing agreement to discover and develop drugs targeting two ion channel targets associated with neurologi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. NewAmsterdam’s Plans For Obicetrapib In